Draft Nice Guidance For The Use Of Abiraterone

EDM number 2706 in 2010-12, proposed by John Leech on 08/02/2012.
Categorised under the topics of Diseases, Health education and preventive medicine and Health services.

That this House notes with serious concern that the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance for the use of the drug abiraterone, a life extending treatment for men in the final stages of prostate cancer, which could, if implemented, prevent the use of this cancer drug for the treatment of this condition in the NHS in England and Wales; is aware that prostate cancer is the most common cancer in men in the UK, that 32,500 men are diagnosed with prostate cancer and that 10,000 men die from the disease in England and Wales every year; further notes that abiraterone can extend the life of men in the final stages of prostate cancerby an average of four months and improves their quality of life; calls on the Government to act immediately to ensure that men with prostate cancer are able to access this treatment to treat their health condition and help to prolong their life; further calls on NICE to reconsider its draft guidance and recommend abiraterone for the benefit of men with prostate cancer and their families; and considers that men should be able to access this drug through the Cancer Drugs Fund, if their clinicians prescribe it, irrespective of this draft decision by NICE.

This motion has been signed by a total of 35 MPs.